Publications by authors named "B A Younis"
Article Synopsis
- The study evaluated a clinical decision tool (CDT) for assessing thoracolumbar fractures in trauma patients, aiming to potentially replace traditional imaging methods to speed up the clearance of the TL spine.
- Conducted on alert trauma patients with suspected injuries, the CDT tested for criteria like pain absence and movement capability to determine fracture presence.
- Results showed the CDT had a high sensitivity (99.38%) for identifying the absence of fractures, but lower specificity (9.1%), indicating it was better at ruling out fractures than confirming them.
Article Synopsis
- A phase 2a clinical trial demonstrated that the leishmaniasis vaccine ChAd63-KH is safe and can generate an immune response in Sudanese patients with post kala-azar dermal leishmaniasis (PKDL).
- A follow-up phase 2b randomized trial assessed its therapeutic efficacy, comparing the vaccine to a placebo in 86 participants with uncomplicated PKDL.
- Results indicated no significant improvement in clinical outcomes or severity of PKDL, suggesting that ChAd63-KH does not provide therapeutic benefits for this condition in the studied population.
This is an interim analysis of the Beta-blocker (Propranolol) use in traumatic brain injury (TBI) based on the high-sensitive troponin status (BBTBBT) study. The BBTBBT is an ongoing double-blind placebo-controlled randomized clinical trial with a target sample size of 771 patients with TBI. We sought, after attaining 50% of the sample size, to explore the impact of early administration of beta-blockers (BBs) on the adrenergic surge, pro-inflammatory cytokines, and the TBI biomarkers linked to the status of high-sensitivity troponin T (HsTnT).
View Article and Find Full Text PDFTreatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to disease-specific variations in absorption, distribution, and elimination. This study characterized PK differences in paromomycin and miltefosine between 109 PKDL and 264 VL patients from Eastern Africa. VL patients showed 0.
View Article and Find Full Text PDFArticle Synopsis
- Immune responses during pneumococcal carriage help protect against Streptococcus pneumoniae colonization and infection, with a study measuring specific IgG levels and opsonic titers in adults with and without type 2 diabetes.
- The study included 176 samples, with findings showing similar IgG concentrations against various serotypes for both groups but higher opsonic titers in non-diabetic individuals, particularly for serotypes 19F and 9V.
- The results suggest that while antibody production is comparable for both capsular polysaccharide and protein antigens in diabetic and non-diabetic individuals, the functional protective capacity of these antibodies differs significantly between the two groups.